Shareholder Votes

TENAX THERAPEUTICS, INC. shareholders approved Ratification of Appointment of Cherry Bekaert LLP as Independent Registered Public Accounting Firm at the 2026-06-02 meeting.

“The Company’s stockholders ratified the appointment of Cherry Bekaert LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 by the votes indicated below.”

TENAX THERAPEUTICS, INC. shareholders approved Election of Directors at the 2026-06-02 meeting.

“The Company’s stockholders elected each of the following individuals to the Company’s Board of Directors for a one-year term expiring in 2027, or until his or her successor is duly elected and qualified, by the votes indicated below.”

Lyft, Inc. shareholders approved Amendment to Restated Certificate of Incorporation to reflect Delaware law provisions regarding officer exculpation at the 2026-06-03 meeting.

“For Against Abstain Broker Non-Votes 247,358,778 16,363,190 424,043 41,487,226”

Lyft, Inc. shareholders approved Amendment to Restated Certificate of Incorporation to remove inoperative provisions, including references to Class B common stock and update other miscellaneous provisions at the 2026-06-03 meeting.

“For Against Abstain Broker Non-Votes 262,132,351 1,569,766 443,894 41,487,226”

Lyft, Inc. shareholders approved Advisory vote on frequency of future stockholder advisory votes on compensation of named executive officers at the 2026-06-03 meeting.

“1 Year 2 Years 3 Years Abstain Broker Non-Votes 259,208,910 1,559,658 3,107,590 269,853 -”

Lyft, Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2026-06-03 meeting.

“For Against Abstain Broker Non-Votes 244,638,672 18,943,909 563,430 41,487,226”

Lyft, Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm at the 2026-06-03 meeting.

“For Against Abstain Broker Non-Votes 304,464,590 780,506 388,141 -”

Lyft, Inc. shareholders approved Election of three Class I directors at the 2026-06-03 meeting.

“David Risher 260,786,797 3,359,214 41,487,226 Deborah Hersman 262,965,316 1,180,695 41,487,226 Dave Stephenson 255,311,965 8,834,046 41,487,226”

MYRIAD GENETICS INC shareholders approved Approval of the Proposed 2026 Employee, Director and Consultant Equity Incentive Plan at the 2026-06-04 meeting.

“Proposal No. 5: Approval of the Proposed 2026 Employee, Director and Consultant Equity Incentive Plan Votes Votes Votes Broker For Against Abstained Non-Votes 59,389,193 3,066,087 48,040 15,255,311 The stockholders voted to approve the 2026 Plan.”

MYRIAD GENETICS INC shareholders approved Approval of the Proposed Amendment to the Amended and Restated 2012 Employee Stock Purchase Plan at the 2026-06-04 meeting.

“Proposal No. 4: Approval of the Proposed Amendment to the Amended and Restated 2012 Employee Stock Purchase Plan Votes Votes Votes Broker For Against Abstained Non-Votes 61,812,338 650,741 40,241 15,255,311 The stockholders voted to approve the proposed amendment to the Purchase Plan to increase the aggregate number of shares of common stock available for issuance under the Purchase Plan by an additional 4,000,000 shares.”

MYRIAD GENETICS INC shareholders approved Approval, on an Advisory Basis, of the Compensation of Our Named Executive Officers, as Disclosed in the Proxy Statement at the 2026-06-04 meeting.

“Proposal No. 3: Approval, on an Advisory Basis, of the Compensation of Our Named Executive Officers, as Disclosed in the Proxy Statement Votes Votes Votes Broker For Against Abstained Non-Votes 59,356,710 3,098,966 47,644 15,255,311 The advisory vote to approve the compensation of the Company's named executive officers, as disclosed in the proxy statement, was approved by stockholders.”

MYRIAD GENETICS INC shareholders approved Ratification of the Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Year Ending December 31, 2026 at the 2026-06-04 meeting.

“Proposal No. 2: Ratification of the Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Year Ending December 31, 2026 Votes Votes Votes For Against Abstained 76,302,595 1,391,172 64,864 The ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 was approved by stockholders.”

MYRIAD GENETICS INC shareholders approved Election of Directors at the 2026-06-04 meeting.

“Proposal No. 1: Election of Directors Votes Votes Votes Broker For Against Abstained Non-Votes Paul M. Bisaro 61,842,900 637,156 23,264 15,255,311 Rashmi Kumar 60,399,633 2,071,375 32,312 15,255,311 Lee N. Newcomer, M.D 61,576,936 894,837 31,547 15,255,311 Each of Paul M. Bisaro, Rashmi Kumar, and Lee N. Newcomer, M.D. was elected to serve as a Class III director of the Company for a term expiring at the 2029 Annual Meeting of Stockholders, and until his or her successor is duly elected and qualified or until his or her earlier death, resignation, retirement or removal.”

Joby Aviation, Inc. shareholders approved Non-binding advisory vote on executive compensation (Say on Pay) at the 2026-06-02 meeting.

“Proposal 3: To approve, in a non-binding advisory vote, the compensation of the Company’s named executive officers (the “Say on Pay Vote”). For Against Abstain Broker Non-Votes 521,136,287 7,363,417 1,930,341 211,377,432”

Joby Aviation, Inc. shareholders approved Ratify appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm at the 2026-06-02 meeting.

“Proposal 2: To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. For Against Abstain 735,837,057 4,057,460 1,912,960”

Joby Aviation, Inc. shareholders approved Election of three Class II directors at the 2026-06-02 meeting.

“Proposal 1: To elect three Class II directors to serve until the 2029 Annual Meeting of Stockholders. Director For Withheld Broker Non-Votes Paul Sciarra 524,737,049 5,692,996 211,377,432 Halimah DeLaine Prado 492,987,240 37,442,805 211,377,432 Laura Wright 521,972,369 8,457,676 211,377,432”

Stoke Therapeutics, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 22, 2026. at the 2026-06-03 meeting.

“Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 22, 2026: Shares For Shares Against Shares Withheld/Abstaining Broker Non-Votes 36,436,275 13,565,293 29,415 5,143,930”

Stoke Therapeutics, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-03 meeting.

“Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: Shares For Shares Against Shares Withheld/Abstaining 55,121,163 2,036 51,714”

Stoke Therapeutics, Inc. shareholders approved Election of three Class I directors, G. Clare Kahn, Ph.D., Adrian Krainer, Ph.D. and Julie Anne Smith, each to serve a three-year term. at the 2026-06-03 meeting.

“Election of three Class I directors, G. Clare Kahn, Ph.D., Adrian Krainer, Ph.D. and Julie Anne Smith, each to serve a three-year term, which will expire upon the earlier of the 2029 annual meeting of stockholders or until such time as their respective successors have been duly elected and qualified or their earlier resignation or removal: Nominees Shares For Shares Withheld Broker Non-Votes G. Clare Kahn, Ph.D. 49,722,339 308,644 5,143,930 Adrian Krainer, Ph.D. 36,531,612 13,499,371 5,143,930 Julie Anne Smith 43,500,649 6,530,334 5,143,930”

VIEMED HEALTHCARE, INC. shareholders approved Advisory vote on executive compensation.

“Shareholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers (the “say-on-pay” vote).”

VIEMED HEALTHCARE, INC. shareholders approved Ratification of Second Amendment to the 2024 LTIP.

“Shareholders approved an ordinary resolution to ratify, confirm, and approve the Second Amendment to the 2024 LTIP.”

VIEMED HEALTHCARE, INC. shareholders approved Appointment of Ernst & Young LLP as independent auditors at the 2026-12-31 meeting.

“Shareholders approved the appointment of Ernst & Young LLP as the Company’s independent auditors for the fiscal year ending December 31, 2026, and authorized the Company's Board of Directors to fix their remuneration.”

VIEMED HEALTHCARE, INC. shareholders approved Election of seven director nominees.

“Shareholders elected each of the seven director nominees to serve until the next annual meeting of shareholders or until their successors are duly elected or appointed.”

VAALCO ENERGY INC /DE/ shareholders approved Approval of the Amendment to increase the number of shares reserved for issuance, revise share reservation and recycling rules, and extend the term of the 2020 LTIP at the 2026-06-04 meeting.

“Proposal No. 4 : Approval of the Amendment to increase the number of shares reserved for issuance, revise share reservation and recycling rules, and extend the term of the 2020 LTIP. Votes Cast For Votes Cast Against Votes Abstained Broker Non-Votes 47,926,781 7,359,271 753,850 18,630,526”

VAALCO ENERGY INC /DE/ shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers at the 2026-06-04 meeting.

“Proposal No. 3 : Approval, on an advisory basis, of the compensation of the Company’s named executive officers. Votes Cast For Votes Cast Against Votes Abstained Broker Non-Votes 53,859,111 1,487,492 693,299 18,630,526”

VAALCO ENERGY INC /DE/ shareholders approved Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-04 meeting.

“Proposal No. 2 : Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Votes Cast For Votes Cast Against Votes Abstained Broker Non-Votes 73,741,558 180,973 747,897 -”

VAALCO ENERGY INC /DE/ shareholders approved Election of five directors at the 2026-06-04 meeting.

“Proposal No. 1 : Election of five directors, each to serve for a one-year term. Nominee Votes Cast For Votes Withheld Broker Non-Votes Andrew L. Fawthrop 51,970,868 4,069,034 18,630,526 George W. M. Maxwell 54,474,662 1,565,240 18,630,526 Cathy Stubbs 54,705,957 1,333,945 18,630,526 Fabrice Nze-Bekale 50,812,199 5,227,703 18,630,526 Edward LaFehr 54,748,788 1,291,114 18,630,526”

Allbirds, Inc. shareholders approved Approval of one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies at the 2026-06-03 meeting.

“Proposal No. 4: To approve one or more adjournments of the Special Meeting from time to time, if necessary, to solicit additional proxies in the event that there are insufficient shares present virtually or represented by proxy voting in favor of the proposals presented at the meeting (the “Adjournment Proposal”). Votes For Votes Against Abstained 26,897,516 28,000 9,497”

Allbirds, Inc. shareholders approved Approval, for purposes of complying with Nasdaq Listing Rule 5635(d), of the issuance of shares of Class A common stock representing more than 19.99% upon conversion of certain Convertible Notes at the 2026-06-03 meeting.

“Proposal No. 3: To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of our Class A common stock representing more than 19.99% upon the conversion of certain Convertible Notes (the “Nasdaq Proposal”). Votes For Votes Against Abstained 26,900,397 29,335 5,281”

Allbirds, Inc. shareholders approved Approval of an amendment to the Ninth Amended and Restated Certificate of Incorporation at the 2026-06-03 meeting.

“Proposal No. 2: To approve an amendment to our Ninth Amended and Restated Certificate of Incorporation (as amended, the “Certificate of Incorporation”) (the “Charter Amendment Proposal”). Votes For Votes Against Abstained 26,898,660 28,038 8,315”

Allbirds, Inc. shareholders approved Approval of the sale of the Purchased Assets of the Company (the Asset Sale) pursuant to the Asset Purchase Agreement at the 2026-06-03 meeting.

“Proposal No. 1: To approve the sale of the Purchased Assets of the Company (the “Asset Sale”) pursuant to the Asset Purchase Agreement dated March 29, 2026 (as it may be amended from time to time, the “Asset Purchase Agreement”), by and between Allbirds, Inc. and Allbirds IP LLC (the “Asset Sale Proposal”). Votes For Votes Against Abstained 26,898,792 28,059 8,162”

EXPAND ENERGY Corp shareholders approved Ratification of Appointment of PwC as Independent Auditor for 2026 at the 2026-06-04 meeting.

“3. Ratification of Appointment of PwC as Independent Auditor for 2026 . Shareholders approved the proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2026. Votes For Votes Against Abstentions Broker Non-Votes 192,751,958 11,582,447 119,648 —”

EXPAND ENERGY Corp shareholders approved Advisory Vote to Approve Named Executive Officer Compensation at the 2026-06-04 meeting.

“2. Advisory Vote to Approve Named Executive Officer Compensation . Shareholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers for 2025. Votes For Votes Against Abstentions Broker Non-Votes 178,548,194 5,243,424 204,268 20,458,167”

EXPAND ENERGY Corp shareholders approved Election of 9 directors nominated by the Board of Directors at the 2026-06-04 meeting.

“Expand Energy Corporation (the "Company") held its 2026 Annual Meeting of Shareholders (the "Annual Meeting") on June 4, 2026. The final voting results for the three proposals voted on at the Annual Meeting are disclosed below. 1. Election of Directors . Shareholders elected each of the 9 directors nominated by the Company’s Board of Directors and listed below”

Kalaris Therapeutics, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-03 meeting.

“The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”

Kalaris Therapeutics, Inc. shareholders approved Advisory vote on the frequency of future advisory votes on executive compensation at the 2026-06-03 meeting.

“The stockholders of the Company recommended, on a non-binding advisory basis, that future advisory votes on the compensation of the Company's named executive officers be held every year.”

Kalaris Therapeutics, Inc. shareholders approved Advisory vote on the compensation of the Company's named executive officers at the 2026-06-03 meeting.

“The stockholders of the Company approved, on a non-binding advisory basis, the compensation of the Company's named executive officers.”

Kalaris Therapeutics, Inc. shareholders approved Election of Class III directors Napoleone Ferrara, M.D., David Hallal and Leone Patterson at the 2026-06-03 meeting.

“The stockholders of the Company elected Napoleone Ferrara, M.D., David Hallal and Leone Patterson as Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified.”

Vontier Corp shareholders approved Approve, on an advisory basis, the Company’s named executive officer compensation as disclosed in the proxy statement for the Annual Meeting at the 2026-06-04 meeting.

“Proposal 3 : To approve, on an advisory basis, the Company’s named executive officer compensation as disclosed in the proxy statement for the Annual Meeting. The proposal was approved, on an advisory basis, by a vote of the Company’s stockholders as follows: For 123,264,464 Against 2,779,529 Abstain 125,718 Broker Non-Votes 5,621,978”

Vontier Corp shareholders approved Ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 at the 2026-06-04 meeting.

“Proposal 2 : To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. The proposal was approved by a vote of the Company’s stockholders as follows: For 131,679,258 Against 47,939 Abstain 64,492”

Vontier Corp shareholders approved Election of directors: Karen C. Francis, Gloria R. Boyland, Robert L. Eatroff, David M. Foulkes, Mark D. Morelli, Maryrose Sylvester and J. Darrell Thomas to serve for an annual term expiring at the 2027 Annual Meeting at the 2026-06-04 meeting.

“Proposal 1 : To elect Karen C. Francis, Gloria R. Boyland, Robert L. Eatroff, David M. Foulkes, Mark D. Morelli, Maryrose Sylvester and J. Darrell Thomas to serve for an annual term expiring at the 2027 Annual Meeting of Stockholders of the Company and until their successors are duly elected and qualified. Each of Mses. Francis, Boyland and Sylvester and Messrs. Eatroff, Foulkes, Morelli and Thomas was elected for an annual term by a vote of the Company’s stockholders as follows: For Against Abstain Broker Non-Votes Karen C. Francis 120,399,316 5,720,850 49,545 5,621,978 Gloria R. Boyland 120,327,034 5,792,894 49,783 5,621,978 Robert L. Eatroff 120,445,887 5,671,834 51,990 5,621,978 David M. Foulkes 123,758,112 2,355,323 56,276 5,621,978 Mark D. Morelli 120,440,378 5,678,758 50,575 5,621,978 Maryrose Sylvester 120,197,545 4,703,652 1,268,514 5,621,978 J. Darrell Thomas 124,223,832 1,894,339 51,540 5,621,978”

Minerva Neurosciences, Inc. shareholders approved Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026 at the 2026-06-03 meeting.

“Proposal 6: Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026. The selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified. The voting results were as follows: For Against Abstain Broker Non-Votes 35,289,299 7,131 1,092 —”

Minerva Neurosciences, Inc. shareholders approved Approval, on an Advisory Basis, of the Frequency of Solicitation of Future Advisory Stockholder Approval of Named Executive Officer Compensation at the 2026-06-03 meeting.

“Proposal 5: Approval, on an Advisory Basis, of the Frequency of Solicitation of Future Advisory Stockholder Approval of Named Executive Officer Compensation. The Company’s stockholders approved Proposal 5. The voting results were as follows: 1 Year 2 Years 3 Years Abstain Broker Non-Votes 30,365,516 1,639 9,934 16,200 4,904,233”

Minerva Neurosciences, Inc. shareholders approved Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers at the 2026-06-03 meeting.

“Proposal 4: Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers, as disclosed in the Proxy Statement. The Company’s stockholders approved Proposal 4. The voting results were as follows: For Against Abstain Broker Non-Votes 27,183,828 3,196,678 12,783 4,904,233”

Minerva Neurosciences, Inc. shareholders approved Approval of an Amendment to our Amended and Restated Certificate of Incorporation to Eliminate the Exclusive Forum Provision at the 2026-06-03 meeting.

“Proposal 3: Approval of an Amendment to our Amended and Restated Certificate of Incorporation to Eliminate the Exclusive Forum Provision. The Company’s stockholders approved Proposal 3. The voting results were as follows: For Against Abstain Broker Non-Votes 30,360,809 20,954 11,526 4,904,233”

Minerva Neurosciences, Inc. shareholders approved Approval of an Amendment to our Amended and Restated Certificate of Incorporation to Reflect Delaware Law Provisions Allowing for the Exculpation of Certain Officers at the 2026-06-03 meeting.

“Proposal 2: Approval of an Amendment to our Amended and Restated Certificate of Incorporation to Reflect Delaware Law Provisions Allowing for the Exculpation of Certain Officers. The Company’s stockholders approved Proposal 2. The voting results were as follows: For Against Abstain Broker Non-Votes 27,222,961 3,169,756 572 4,904,233”

Minerva Neurosciences, Inc. shareholders approved Election of Directors at the 2026-06-03 meeting.

“Proposal 1: Election of Directors. Two nominees were elected to serve on the Board until the Company’s 2029 annual meeting of stockholders and until their successors are elected and qualified. The voting results were as follows: Nominee For Withheld Broker Non-Votes Dr. David Kupfer 23,211,099 7,182,190 4,904,233 Jan van Heek 30,369,333 23,956 4,904,233”

Kura Oncology, Inc. shareholders approved Approval of our Amended ESPP at the 2026-06-04 meeting.

“Proposal 6. Approval of our Amended ESPP For Against Abstain Broker Non-Votes 58,306,174 213,434 161,424 11,097,548”

Kura Oncology, Inc. shareholders approved Approval of our Amended 2014 Plan at the 2026-06-04 meeting.

“Proposal 5. Approval of our Amended 2014 Plan For Against Abstain Broker Non-Votes 48,402,820 10,099,296 178,916 11,097,548”

Kura Oncology, Inc. shareholders approved Advisory Indication on Frequency of Stockholder Advisory Votes on Executive Compensation at the 2026-06-04 meeting.

“Proposal 4. Advisory Indication on Frequency of Stockholder Advisory Votes on Executive Compensation 1 Year 2 Years 3 Years Abstain Broker Non-Votes 48,362,762 54,055 1,586,672 8,677,543 11,097,548”